AR053014A1 - Compuestos de pirazol inhibidores de raf quinasa - Google Patents
Compuestos de pirazol inhibidores de raf quinasaInfo
- Publication number
- AR053014A1 AR053014A1 ARP060100401A ARP060100401A AR053014A1 AR 053014 A1 AR053014 A1 AR 053014A1 AR P060100401 A ARP060100401 A AR P060100401A AR P060100401 A ARP060100401 A AR P060100401A AR 053014 A1 AR053014 A1 AR 053014A1
- Authority
- AR
- Argentina
- Prior art keywords
- nr20r21
- alkyl
- aryl
- heterocyclyl
- alkynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Los compuestos de pirazolilo de formulas (1) y (2) son utiles para inhibir la Raf quinasa y para el tratamiento de trastornos mediados por la misma. Se revelan métodos para el uso de compuestos de pirazolilo para el diagnostico in vitro, in situ e in vivo, el tratamiento o prevencion de dichos trastornos en células mamíferas, o afecciones patologicas asociadas. Composiciones farmacéuticas. Métodos de obtencion. Reivindicacion 1. Un compuesto seleccionado de formula (1) y (2), y sus estereoisomeros, tautomeros, solvatos y sales aceptables para uso farmacéutico en las cuales: el anillo A es: i) un anillo heterocíclico de 5 o 6 miembros que tiene uno o dos heteroátomos independientemente seleccionados de O, N, y S, ii) un anillo carbocíclico de 5 o 6 miembros opcionalmente fusionado a un heterociclo de 5 o 6 miembros, o iii) un anillo fenilo, donde dichos anillos heterocíclicos, carbocíclicos y fenilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente de F, Cl, Br, I, -C(=Y)R20, -C(=Y)OR20, -C(=Y)NR20R21, NR20R21, -NR20C(=Y)R21, -NR20C(=Y)OR21, -NR23C(=Y)NR20R21, =NOR20, =NR20, =N+(O)OR20, =NNR20R21, =O, -OR20, -OC(=Y)R20, -OC(=Y)OR20, - OC(=Y)NR20R21, -OS(O)2(OR20), - OP(=Y)(OR20)(OR21), -OP(OR20)(OR21), - P(=Y)(OR20)(OR21), -P(=Y)(OR)NR20R21, =S, -SR20, -S(O)R20, -S(O)2R20, -S(O)2NR20R21, -S(O)(OR20), -S(O)2(OR20), -SC(=Y)R20, -SC(=Y)OR20, - SC(=Y)NR20R21, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilo C6- 20, carbociclilo C3-12, heterociclilo C2-20, y un grupo protector, y donde dicho alquilo, alquenilo, alquinilo, arilo, carbociclilo y heterociclilo están opcional e independientemente sustituidos con uno o más grupos seleccionados independientemente de F, Cl, Br, I, -C(=Y)R20, -C(=Y)OR20, -C(=Y)NR20R21, NR20R21, -NR20C(=Y)R21, -NR20C(=Y)OR21, - NR23C(=Y)NR20R21, -OR20, -OC(=Y)R20, -OC(=Y)OR20, -OC(=Y)NR20R21, - OS(O)2(OR20), -OP(=Y)(OR20)(OR21), -OP(OR20)(OR21), -P(=Y)(OR20)(OR21), - P(=Y)(OR)NR20R21, -SR20, -S(O)R20, -S(O)2R20, -S(O)2NR20R21, -S(O)(OR20), - S(O)2(OR20), -SC(=Y)R20, -SC(=Y)OR20, -SC(=Y)NR20R21, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilo C6-2O, carbociclilo C3-12, heterociclilo C2-20; X se selecciona de un heterociclilo C2-20, un carbociclilo C3-12, y un arilo C6-20, donde dicho heterociclo, carbociclilo y arilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente de F, Cl, Br, I, -C(=Y)R20, -C(=Y)OR20, - C(=Y)NR20R21, -NR20R21, -NR20C(=Y)R21, -NR20C(=Y)OR21, -NR23C(=Y)NR20R21, - OR20, -OC(=Y)R20, -OC(=Y)OR20, -OC(=Y)NR20R21, -OS(O)2(OR20), - OP(=Y)(OR20)(OR21), -OP(OR20)(OR21), -P(=Y)(OR20)(OR21), -P(=Y)(OR23)NR20R21, - SR20, -S(O)R20, -S(O)2R20, - S(O)2NR20R21, -S(O)(OR20), -S(O)2(OR20), -SC(=Y)R20, - SC(=Y)OR20, -SC(=Y)NR20R21, lactama de 5-7 miembros en el anillo, lactona de 5 a 7 miembros en el anillo, sultama de 5 a 7 miembros en el anillo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, arilo C6-20, y heterociclilo C2-20, donde dicho alquilo, alquenilo, alquinilo, carbociclilo, arilo, y heterociclilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente de F, Cl, Br, I, OR20, NR20R21 -SR20, -S(O)R20, -S(O)2R20, alquilo, alquenilo, alquinilo, carbociclilo, arilo y heterociclilo; R1 se selecciona H, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, alquiloC1-8NR20R21, un heterociclilo C2-20, un carbociclilo C3-12, y un arilo C6-20, donde dicho alquilo, alquenilo, alquinilo, heterociclo, carbociclilo y arilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente de F, Cl, Br, I, -C(=Y)R20, -C(=Y)OR20, -C(=Y)NR20R21, -NR20R21, OR20, CN, C(=O)NR20R21, C(=O)OR20, alquilo, alquiloC1-8 NR20R21, y heterociclilo; R2 se selecciona de H, F, Cl, Br, I, -C(=Y)R20, -C(=Y)OR20, -C(=Y)NR20R21, -OR20, -OC(=Y)R20, -OC(=Y)OR20, -OC(=Y)NR20R21, -OS(O)2(OR20), - OP(=Y)(OR20)(OR21), -OP(OR20)(OR21), - P(=Y)(OR20)(OR21), -P(=Y)(OR)NR20R21, - SR20, -S(O)R20, -S(O)2R20, -S(O)2NR20R21, -S(O)(OR20), -S(O)2(OR20), -SC(=Y)R20, - SC(=Y)OR20, -SC(=Y)NR20R21, lactama de 5-7 miembros en el anillo, lactona de 5 a 7 miembros en el anillo, sultama de 5 a 7 miembros en el anillo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, arilo C6-20, y heterociclilo C2-20, donde dicho alquilo, alquenilo, alquinilo, carbociclilo, arilo, y heterociclilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente de F, Cl, Br, I, OR20, NR20R21 -SR20, -S(O)R20, -S(O)2R20, alquilo, alquenilo, alquinilo, carbociclilo, arilo y heterociclilo; o R1 y R2 de Formula (1) junto con los átomos a los cuales están unidos opcionalmente forman un anillo heterociclo fusionado de 5 o 6 miembros, saturado, parcialmente saturado o aromático que tienen al menos dos heteroátomos seleccionados independientemente de O, N y S, donde dicho anillo heterociclo está opcionalmente sustituido con uno o más grupos seleccionados independientemente de F, Cl, Br, I, -C(=Y)R20, -C(=Y)OR20, -C(=Y)NR20R21, -NR20R21, -NR20C(=Y)R21, -NR20C(=Y)OR21, -NR23C(=Y)NR20R21, -OR20, -OC(=Y)R20, -OC(=Y)OR20, -OC(=Y)NR20R21, -OS(O)2(OR20), - OP(=Y)(OR20)(OR21), - OP(OR20)(OR21), -P(=Y)(OR20)(OR21), -P(=Y)(OR23)NR20R21, -SR20, -S(O)R20, - S(O)2R20, -S(O)2NR20R21, -S(O)(OR20), -S(O)2(OR20), -SC(=Y)R20, -SC(=Y)OR20, - SC(=Y)NR20R21, lactama de 5-7 miembros en el anillo, lactona de 5 a 7 miembros en el anillo, sultama de 5 a 7 miembros en el anillo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, arilo C6-20, y heterociclilo C2-20, donde dicho alquilo, alquenilo, alquinilo, carbociclilo, arilo, y heterociclilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente de F, Cl, Br, I, OR20, NR20R21 -SR20, -S(O)R20, -S(O)2R20, alquilo, alquenilo, alquinilo, carbociclilo, arilo y heterociclilo; R3, R4, y R5 se seleccionan independientemente de H, F, Cl, Br, I, -C(=Y)R20, - C(=Y)OR20, -C(=Y)NR20R21, -NR20R21, -NR20C(=Y)R21, -NR20C(=Y)OR21, -NR23C(=Y)NR20R21, -OR20, -OC(=Y)R20, -OC(=Y)OR20, -OC(=Y)NR20R21, - OS(O)2(OR20), -OP(=Y)(OR20)(OR21), -OP(OR20)(OR21), - P(=Y)(OR20)(OR21), - P(=Y)(OR23)NR20R21, -SR20, -S(O)R20, -S(O)2R20, -S(O)2NR20R21, -S(O)(OR20), -S(O)2(OR20), -SC(=Y)R20, -SC(=Y)OR20, -SC(=Y)NR20R21, lactama de 5-7 miembros en el anillo, lactona de 5 a 7 miembros en el anillo, sultama de 5 a 7 miembros en el anillo, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, carbociclilo C3-12, arilo C6-20, y heterociclilo C2-20, donde dicho alquilo, alquenilo, alquinilo, carbociclilo, arilo, y heterociclilo están opcionalmente sustituidos con uno o más grupos seleccionados independientemente de F, Cl, Br, I, OR20, NR20R21 -SR20, -S(O)R20, -S(O)2R20, alquilo, alquenilo, alquinilo, carbociclilo, arilo y heterociclilo; R20 y R21 se seleccionan independientemente de H, alquilo C1-8, alquenilo C2- 8, alquinilo C2-8, arilo C6-20, heterociclilo C2-20, y un grupo protector, donde dicho alquilo, alquenilo, alquinilo, arilo y heterociclilo están opcional e independientemente sustituidos con uno o más grupos seleccionados independientemente de F, Cl, Br, I, -C(=Y)Ra, -C(=Y)ORa, -C(=Y)NRaRb, -ORa, -OC(=Y)Ra, -OC(=Y)ORa, -OC(=Y)NRaRb, -OS(O)2(ORa), -OP(=Y)(ORa)(ORb), -OP(ORa)(ORb), -P(=Y)(ORa)(ORb), - P(=Y)(OR)NRaRb, -SRa, -S(O)Ra, -S(O)2Ra, -S(O)2NRaRb, -S(O)(ORa), -S(O)2(ORa), -SC(=Y)Ra, - SC(=Y)ORa, y -SC(=Y)NRaRb, o R20 y R21 junto con los átomos a los cuales están unidos forman un anillo heterocíclico, donde dicho anillo heterocíclico está opcionalmente sustituido con uno o más grupos seleccionados independientemente de F, Cl, Br, I, alquilo, alquenilo y alquinilo; R23 es H, alquilo C1-8, alquenilo C2-8, alquinilo C2-8 o, arilo C6-20, heterociclilo C2-20, o un grupo protector; Ra y Rb son independientemente H, alquilo C1-8, alquenilo C2-8, alquinilo C2-8, arilo C6-20, o heterociclilo C2-20; Y es independientemente O, S, NR20, +N(O)R20, N(OR20), +N(O)(OR20), o N-NR20R21; y grupo protector se selecciona de trialquilsililo, dialquilfenilsililo, benzoato, bencilo, benciloximatilo, metilo, metoximetilo, triarilmetilo, ftalimido, t-butoxicarbonilo (BOC), benciloxicarbonilo (CBz), 9-fluorenilmetilenoxicarbonilo (Fmoc), y tetrahidropiranilo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65005005P | 2005-02-04 | 2005-02-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053014A1 true AR053014A1 (es) | 2007-04-18 |
Family
ID=36571626
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100401A AR053014A1 (es) | 2005-02-04 | 2006-02-03 | Compuestos de pirazol inhibidores de raf quinasa |
Country Status (18)
Country | Link |
---|---|
US (2) | US7491829B2 (es) |
EP (1) | EP1846391A2 (es) |
JP (1) | JP2008530011A (es) |
KR (1) | KR20070107104A (es) |
CN (1) | CN101282960A (es) |
AR (1) | AR053014A1 (es) |
AU (1) | AU2006210626A1 (es) |
BR (1) | BRPI0607346A2 (es) |
CA (1) | CA2596973A1 (es) |
CR (1) | CR9365A (es) |
IL (1) | IL185024A0 (es) |
MA (1) | MA29310B1 (es) |
MX (1) | MX2007009405A (es) |
NO (1) | NO20074473L (es) |
RU (1) | RU2007133111A (es) |
TW (1) | TW200639163A (es) |
WO (1) | WO2006084015A2 (es) |
ZA (1) | ZA200707289B (es) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008042639A1 (en) | 2006-10-02 | 2008-04-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
CA2667053C (en) | 2006-10-17 | 2015-04-28 | Stiefel Laboratories, Inc. | Talarazole metabolites |
WO2009039387A1 (en) * | 2007-09-20 | 2009-03-26 | Wyeth | Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof |
CA2716947A1 (en) * | 2008-02-29 | 2009-09-11 | Array Biopharma Inc. | Imidazo [4,5-b] pyridine derivatives used as raf inhibitors |
KR20100117686A (ko) * | 2008-02-29 | 2010-11-03 | 어레이 바이오파마 인크. | 피라졸[3,4-b]피리딘 raf 저해물질 |
WO2009111260A1 (en) * | 2008-02-29 | 2009-09-11 | Wyeth | Phenylsulfonamide-substituted, pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
JP2011513332A (ja) | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | 癌の治療のためのraf阻害剤としてのn−(6−アミノピリジン−3−イル)−3−(スルホンアミド)ベンズアミド誘導体 |
WO2009108827A1 (en) * | 2008-02-29 | 2009-09-03 | Wyeth | Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof |
EP2265608A2 (en) * | 2008-02-29 | 2010-12-29 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
JP2009286773A (ja) * | 2008-03-14 | 2009-12-10 | Bayer Cropscience Ag | 殺虫性縮環式アリール類 |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
US8912330B2 (en) | 2008-12-12 | 2014-12-16 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
US8765747B2 (en) | 2009-06-12 | 2014-07-01 | Dana-Farber Cancer Institute, Inc. | Fused 2-aminothiazole compounds |
EP2470532A1 (en) | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | 1h-pyrazolo [ 3, 4-b]pyridine compounds for inhibiting raf kinase |
JP2013503187A (ja) | 2009-08-28 | 2013-01-31 | アレイ バイオファーマ、インコーポレイテッド | Raf阻害化合物およびその使用方法 |
EP2470541A1 (en) | 2009-08-28 | 2012-07-04 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
CA2771895A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
CA2772575A1 (en) * | 2009-08-28 | 2011-03-03 | Genentech, Inc. | Raf inhibitor compounds and methods of use thereof |
WO2011025940A1 (en) | 2009-08-28 | 2011-03-03 | Array Biopharma Inc. | Raf inhibitor compounds and methods of use thereof |
CA2779073C (en) * | 2009-10-30 | 2017-10-24 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
EP2519517B1 (en) | 2009-12-29 | 2015-03-25 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
SG182297A1 (en) | 2009-12-31 | 2012-08-30 | Ct Nac Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
US20120122928A1 (en) | 2010-08-11 | 2012-05-17 | Bayer Cropscience Ag | Heteroarylpiperidine and -Piperazine Derivatives as Fungicides |
US8759527B2 (en) | 2010-08-25 | 2014-06-24 | Bayer Cropscience Ag | Heteroarylpiperidine and -piperazine derivatives as fungicides |
EP2423210A1 (de) | 2010-08-25 | 2012-02-29 | Bayer CropScience AG | Heteroarylpiperidin- und -piperazinderivate als Fungizide |
CA2815716C (en) | 2010-10-27 | 2019-06-11 | Bayer Intellectual Property Gmbh | Heteroaryl piperidine and heteroaryl piperazine derivatives as fungicides |
CN103298808A (zh) | 2011-01-06 | 2013-09-11 | 加拿大贝达药业有限公司 | 用于治疗和预防癌症的新脲类化合物 |
WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
JP6326231B2 (ja) | 2011-02-01 | 2018-05-16 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 殺菌剤としてのヘテロアリールピペリジン誘導体及びヘテロアリールピペラジン誘導体 |
WO2012145503A1 (en) | 2011-04-21 | 2012-10-26 | Novartis Ag | Pharmaceutical combinations |
AU2012250517B2 (en) | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
MY193562A (en) | 2011-08-01 | 2022-10-19 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
SG11201400724SA (en) | 2011-09-19 | 2014-04-28 | Genentech Inc | Combination treatments comprising c-met antagonists and b-raf antagonists |
EP2822935B1 (en) | 2011-11-17 | 2019-05-15 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
DK2921492T3 (en) | 2011-12-27 | 2017-12-11 | Bayer Ip Gmbh | HETEROARYLPIPERIDINE AND ¿PIPERAZINE DERIVATIVES |
EP3124472B1 (en) | 2011-12-31 | 2018-07-25 | BeiGene, Ltd. | Fused tricyclic compounds as raf kinase inhibitors |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
ES2743427T3 (es) | 2012-08-17 | 2020-02-19 | Hoffmann La Roche | Politerapias para melanoma que comprenden administrar cobimetinib y vemurafinib |
EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
WO2014063061A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
JP2016509045A (ja) | 2013-02-22 | 2016-03-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | がんを治療し、薬剤耐性を防止する方法 |
JO3383B1 (ar) * | 2013-03-14 | 2019-03-13 | Lilly Co Eli | مثبطات cdc7 |
WO2014144850A1 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Methods of treating cancer and preventing cancer drug resistance |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9670231B2 (en) | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
US20160264551A1 (en) | 2013-10-18 | 2016-09-15 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
EP3057956B1 (en) | 2013-10-18 | 2021-05-05 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
RU2016141385A (ru) | 2014-03-24 | 2018-04-28 | Дженентек, Инк. | Лечение рака антагонистами с-мет и их корреляция с экспрессией hgf |
US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
CN107073121A (zh) | 2014-06-13 | 2017-08-18 | 基因泰克公司 | 治疗及预防癌症药物抗性的方法 |
US20170114323A1 (en) * | 2014-06-19 | 2017-04-27 | Whitehead Institute For Biomedical Research | Uses of kinase inhibitors for inducing and maintaining pluripotency |
WO2016000619A1 (en) | 2014-07-03 | 2016-01-07 | Beigene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
PL3169361T3 (pl) | 2014-07-15 | 2019-11-29 | Hoffmann La Roche | Kompozycje do leczenia nowotworu z użyciem związków antagonistycznych wiązania osi pd-1 i inhibitorów mek |
NZ728688A (en) | 2014-07-22 | 2023-06-30 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
RU2722212C9 (ru) | 2014-08-05 | 2020-07-23 | СиБи ТЕРЕПЬЮТИКС, ИНК. | Анти-pd-l1 антитела |
WO2016105528A2 (en) | 2014-12-23 | 2016-06-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
US10550121B2 (en) | 2015-03-27 | 2020-02-04 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
MX2017013219A (es) | 2015-04-15 | 2018-02-15 | Beigene Ltd | Sales de maleato de un inhibidor de b-raf quinasa, formas cristalinas, metodos de preparacion y por consiguiente sus usos. |
WO2016201370A1 (en) | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
AU2016355320B2 (en) | 2015-11-19 | 2023-12-07 | Genentech, Inc. | Methods of treating cancer using B-RAF inhibitors and immune checkpoint inhibitors |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
EP4353747A2 (en) | 2016-08-19 | 2024-04-17 | BeiGene Switzerland GmbH | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer |
KR102173464B1 (ko) | 2016-12-01 | 2020-11-04 | 아비나스 오퍼레이션스, 인코포레이티드 | 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체 |
KR102564201B1 (ko) * | 2016-12-23 | 2023-08-07 | 아비나스 오퍼레이션스, 인코포레이티드 | 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법 |
US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
WO2019133810A1 (en) | 2017-12-28 | 2019-07-04 | Tract Pharmaceuticals, Inc. | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
WO2021120890A1 (en) * | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
TW202233607A (zh) * | 2020-10-30 | 2022-09-01 | 瑞士商諾華公司 | Kras g12c抑制劑化合物之新結晶形式 |
AU2022401750A1 (en) * | 2021-11-30 | 2024-02-15 | Abbisko Therapeutics Co., Ltd. | Pyrazole derivative, and preparation method therefor and use thereof in medicine |
WO2024022186A1 (zh) * | 2022-07-29 | 2024-02-01 | 四川科伦博泰生物医药股份有限公司 | 甲基吡唑化合物、包含其的药物组合物及其制备方法和用途 |
US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1245283A (en) | 1968-10-04 | 1971-09-08 | Labaz | Pyrazole derivatives |
JP2753659B2 (ja) | 1990-09-03 | 1998-05-20 | 株式会社大塚製薬工場 | ピラゾール誘導体 |
US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
JPH05125079A (ja) | 1991-11-05 | 1993-05-21 | Otsuka Pharmaceut Factory Inc | ピラゾロ[1,5−aピリミジン誘導体 |
CN1046730C (zh) | 1994-06-21 | 1999-11-24 | 株式会社大塚制药工场 | 吡唑并[1,5-a]嘧啶衍生物 |
US5486534A (en) | 1994-07-21 | 1996-01-23 | G. D. Searle & Co. | 3,4-substituted pyrazoles for the treatment of inflammation |
CA2206080A1 (en) | 1995-09-28 | 1997-04-03 | Otsuka Pharmaceutical Factory, Inc. | Analgesic composition_of pryazolo{1,5-a}pyrimidine derivatives |
JPH10101672A (ja) | 1996-08-06 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | アデノシン増強剤 |
JPH10101671A (ja) | 1996-08-08 | 1998-04-21 | Otsuka Pharmaceut Factory Inc | 一酸化窒素合成酵素阻害剤 |
WO1998052937A2 (en) | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | 4-aryl-3(5)-heteroaryl substituted pyrazoles as p38 kinase |
US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
JP2000153671A (ja) | 1998-11-20 | 2000-06-06 | Fuji Photo Film Co Ltd | 感熱記録材料 |
AU4556800A (en) | 1999-04-27 | 2000-11-10 | Smithkline Beecham Plc | Novel treatment |
TWI271406B (en) | 1999-12-13 | 2007-01-21 | Eisai Co Ltd | Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same |
AU2001236720A1 (en) | 2000-02-05 | 2001-08-14 | Bemis, Guy | Compositions useful as inhibitors of erk |
NZ514583A (en) | 2000-02-05 | 2004-05-28 | Vertex Pharma | Pyrazole compositions useful as inhibitors of ERK |
EP1196390A2 (en) | 2000-02-05 | 2002-04-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compositions useful as inhibitors of erk |
ES2218391T3 (es) | 2000-03-06 | 2004-11-16 | Smithkline Beecham Plc | Derivados de imidazol como inhibidores de raf-cinasa. |
CA2423154A1 (en) | 2000-09-21 | 2002-03-28 | David Kenneth Dean | Imidazole derivatives as raf kinase inhibitors |
ATE375345T1 (de) | 2000-12-28 | 2007-10-15 | Ono Pharmaceutical Co | Cyclopenta(d)pyrazolo(1,5-a)pyrimidin-verbindun als crf-rezeptor antagonist |
ATE377598T1 (de) | 2001-01-22 | 2007-11-15 | Sankyo Co | Durch bicyclische aminogruppen substituierte verbindungen |
MXPA03008142A (es) * | 2001-03-09 | 2003-12-12 | Pfizer Prod Inc | Nuevos compuestos antiinflamatorios de bencimidazol. |
DE60227794D1 (de) * | 2001-04-26 | 2008-09-04 | Eisai R&D Man Co Ltd | Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon |
GB0112348D0 (en) | 2001-05-19 | 2001-07-11 | Smithkline Beecham Plc | Compounds |
CN1951939A (zh) * | 2001-05-24 | 2007-04-25 | 伊莱利利公司 | 作为药物的新的吡唑衍生物 |
ATE392421T1 (de) | 2001-08-03 | 2008-05-15 | Vertex Pharma | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
CA2456187A1 (en) | 2001-08-03 | 2003-02-13 | Qing Tang | Pyrazole-derived kinase inhibitors and uses thereof |
GB0121490D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Ciompounds |
GB0121494D0 (en) | 2001-09-05 | 2001-10-24 | Smithkline Beecham Plc | Compounds |
US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
US20040010027A1 (en) * | 2001-12-17 | 2004-01-15 | Pharmacia & Upjohn Spa | Hydroxphenyl-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical comositions comprising them |
ES2295441T3 (es) * | 2001-12-18 | 2008-04-16 | MERCK & CO., INC. | Moduladores de pirazol heteroaril sustituido de receptor 5 metabotropico de glutamato. |
AU2002356301A1 (en) | 2001-12-21 | 2003-07-15 | Cancer Research Technology Ltd. | 3,4-diarylpyrazoles and their use in the therapy of cancer |
AU2003228770A1 (en) | 2002-05-10 | 2003-11-11 | Smithkline Beecham Corporation | Substituted pyrazolopyrimidines |
GB0217786D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
JP2005539000A (ja) | 2002-07-31 | 2005-12-22 | スミスクライン・ビーチャム・コーポレイション | Alk5阻害剤としての2−フェニルピリジン−4−イル誘導体 |
EP1554272B1 (en) * | 2002-08-09 | 2006-10-25 | Eli Lilly And Company | Benzimidazoles and benzothiazoles as inhibitors of map kinase |
US6967254B2 (en) | 2002-09-09 | 2005-11-22 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
DE60315677T2 (de) | 2002-09-17 | 2008-06-05 | Eli Lilly And Co., Indianapolis | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs |
BR0314302A (pt) | 2002-09-18 | 2005-07-05 | Pfizer Producs Inc | Compostos de pirazol como inibidores do fator de crescimento trnasformante (tgf) |
AU2003268155A1 (en) | 2002-09-19 | 2004-04-08 | Eli Lilly And Company | Methods of inhibiting tgf beta with substituted pyrazoles |
US7405299B2 (en) * | 2002-11-27 | 2008-07-29 | Eli Lilly And Company | Compounds as pharmaceutical agents |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
CL2004000234A1 (es) | 2003-02-12 | 2005-04-15 | Biogen Idec Inc | Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid |
GB0313915D0 (en) * | 2003-06-16 | 2003-07-23 | Smithkline Beecham Corp | Compounds |
-
2006
- 2006-01-27 TW TW095103640A patent/TW200639163A/zh unknown
- 2006-02-02 AU AU2006210626A patent/AU2006210626A1/en not_active Abandoned
- 2006-02-02 JP JP2007554205A patent/JP2008530011A/ja active Pending
- 2006-02-02 MX MX2007009405A patent/MX2007009405A/es not_active Application Discontinuation
- 2006-02-02 US US11/345,828 patent/US7491829B2/en not_active Expired - Fee Related
- 2006-02-02 EP EP06734199A patent/EP1846391A2/en not_active Withdrawn
- 2006-02-02 RU RU2007133111/04A patent/RU2007133111A/ru not_active Application Discontinuation
- 2006-02-02 CN CNA2006800109351A patent/CN101282960A/zh active Pending
- 2006-02-02 CA CA002596973A patent/CA2596973A1/en not_active Abandoned
- 2006-02-02 BR BRPI0607346-8A patent/BRPI0607346A2/pt not_active IP Right Cessation
- 2006-02-02 WO PCT/US2006/003654 patent/WO2006084015A2/en active Application Filing
- 2006-02-02 KR KR1020077020119A patent/KR20070107104A/ko not_active Application Discontinuation
- 2006-02-03 AR ARP060100401A patent/AR053014A1/es not_active Application Discontinuation
-
2007
- 2007-08-02 IL IL185024A patent/IL185024A0/en unknown
- 2007-08-17 MA MA30151A patent/MA29310B1/fr unknown
- 2007-08-28 ZA ZA200707289A patent/ZA200707289B/xx unknown
- 2007-09-03 NO NO20074473A patent/NO20074473L/no not_active Application Discontinuation
- 2007-09-04 CR CR9365A patent/CR9365A/es not_active Application Discontinuation
-
2008
- 2008-12-31 US US12/347,412 patent/US20090176809A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101282960A (zh) | 2008-10-08 |
IL185024A0 (en) | 2007-12-03 |
US20090176809A1 (en) | 2009-07-09 |
CR9365A (es) | 2008-01-15 |
RU2007133111A (ru) | 2009-03-10 |
MA29310B1 (fr) | 2008-03-03 |
KR20070107104A (ko) | 2007-11-06 |
US20060189627A1 (en) | 2006-08-24 |
WO2006084015A2 (en) | 2006-08-10 |
EP1846391A2 (en) | 2007-10-24 |
NO20074473L (no) | 2007-10-31 |
ZA200707289B (en) | 2009-09-30 |
WO2006084015A3 (en) | 2006-11-23 |
AU2006210626A1 (en) | 2006-08-10 |
MX2007009405A (es) | 2007-09-25 |
JP2008530011A (ja) | 2008-08-07 |
TW200639163A (en) | 2006-11-16 |
CA2596973A1 (en) | 2006-08-10 |
US7491829B2 (en) | 2009-02-17 |
BRPI0607346A2 (pt) | 2009-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053014A1 (es) | Compuestos de pirazol inhibidores de raf quinasa | |
AR058379A1 (es) | Derivados de arilpropionamida arilacrilamida arilpropinamida o arilmetilurea como inhibidores del factor xia. proceso de obtencion y composiciones farmaceuticas. | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
PE20050158A1 (es) | Compuestos inmunosupresores y composiciones | |
AR090191A1 (es) | Derivados del acido fenil alcanoico como agonistas gpr | |
ES2600028T3 (es) | Inhibidores selectivos de la glucosidasa y sus usos | |
ES2655911T3 (es) | Compuestos de tetraciclina sustituidos con C7-fluoro | |
AR064304A1 (es) | Formulaciones de ansamicina y sus metodos de uso | |
AR060633A1 (es) | Derivados de furo[3, 2-d]pirimidina, furo[2, 3-d]pirimidina, tieno[3, 2-d]pirimidina y tieno[2, 3-d]pirimidina, metodos para su preparacion, composiciones farmaceuticas y obtencion de las mismas, el uso de estos derivados en la fabricacion de medicamentos, kits y productos para el tratamiento de enf | |
AR086729A1 (es) | Composiciones pesticidas y los procesos relacionados con las mismas | |
AR053710A1 (es) | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos | |
AR041997A1 (es) | Derivados de oxaxol sustituidos, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de la diabetes | |
AR030696A1 (es) | Derivados de hidroxi-1-azobenceno, composiciones farmaceuticas que los comprenden, uso de dichos compuestos en la fabricacion de medicamentos, proceso para preparar dichas composiciones, proceso para preparar dichos compuestos, metodo in vitro o ex vivo para aumentar la estimulacion de la maduracion | |
AR082994A1 (es) | Derivados de pirazina como bloqueadores del canal epitelial de sodio | |
AR068840A1 (es) | Moduladores del gpr40 bifenilo sustituidos y composiciones farmaceuticas que los contienen | |
AR066459A1 (es) | Derivados de oxadiazol como moduladores de gamma-secretasa. composiciones farmaceuticas | |
AR076188A1 (es) | Derivados de oxadiazol | |
AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
PE20090620A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
PE20191103A1 (es) | Inhibidores de dopamina-b-hidroxilasa | |
CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
AR039927A1 (es) | Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen | |
AR062399A1 (es) | Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido | |
AR096041A1 (es) | Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |